Alterity Therapeutics (ATHE) Liabilities and Shareholders Equity (2009 - 2025)

Alterity Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $37.4 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 441.83% year-over-year to $37.4 million in Q4 2025; TTM through Dec 2025 was $86.4 million, a 152.04% increase from a year earlier, with the FY2025 full-year figure at $29.5 million, up 132.67% from the prior year.
• Liabilities and Shareholders Equity advanced to $37.4 million in Q4 2025 per ATHE's latest filing, from $29.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $37.4 million in Q4 2025 and bottomed at $273176.4 in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $23.9 million (2022), against an average of $21.1 million.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 99.08% in 2023 and surged 4537.63% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $32.7 million in 2021, then sank by 32.99% to $21.9 million in 2022, then tumbled by 34.13% to $14.4 million in 2023, then plunged by 52.26% to $6.9 million in 2024, then surged by 441.83% to $37.4 million in 2025.
• Per Business Quant, the three latest ATHE Liabilities and Shareholders Equity figures stand at $37.4 million (Q4 2025), $29.5 million (Q2 2025), and $6.9 million (Q4 2024).